Moreover, as tumors in the TCGA dataset are pre-treatment primary tumors, these results indicated that the 89-gene signature might represent an intrinsic tumor composition that confers trastuzumab response in HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.